WO2023285681 - PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
National phase entry is expected:
Publication Number
WO/2023/285681
Publication Date
19.01.2023
International Application No.
PCT/EP2022/069915
International Filing Date
15.07.2022
Title **
[English]
PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER
[French]
COMBINAISONS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER
Applicants **
SPEXIS AG
Hegenheimermattweg 125
4123 Allschwil, CH
Inventors
ZIMMERMANN, Johann
Königsbergerstrasse 9
79379 Müllheim, DE
BERTONI, Francesco
Via Belsoggiorno 20
6500 Bellinzona, CH
ARRIBAS CARMENA, Jesus Alberto
Piazzale Marconi 35
21016 Luino, IT
Priority Data
21020371.7
16.07.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1961 | |
| EPO | Filing, Examination | 8561 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3360 |
Total: 15048 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to pharmaceutical combinations comprising a peptidic CXCR4 inhibitor and a phosphatidylinositol-3-kinase (PI3K) inhibitor for use in a method for the prevention, delay of progression or treatment of cancer.[French]
La présente invention concerne des combinaisons pharmaceutiques comprenant un inhibiteur de CXCR4 peptidique et un inhibiteur de phosphatidylinositol-3-kinase (PI3K) destinées à être utilisées dans un procédé pour prévenir, retarder la progression du cancer ou le traiter.